← Back to Skills Marketplace
Eisas
by
hanxueyuan
· GitHub ↗
· v1.0.0
· MIT-0
37
Downloads
0
Stars
0
Active Installs
1
Versions
Install in OpenClaw
/install eisas
Description
Japanese pharmaceutical company specializing in CNS and oncology drugs, known for Alzheimer's treatments like Aricept and Leqembi in global markets.
README (SKILL.md)
Eisai — Advancing Brain Health
历史时间线
- 1941: Eisai Co., Ltd. founded in Tokyo by Takejiro Ueno
- 1960s-70s: Expands into prescription pharmaceuticals
- 1990s: Establishes US subsidiary, begins global expansion
- 2010: Aricept (donepezil) becomes one of the best-selling Alzheimer's drugs ever
- 2019: Lecanemab (Leqembi) receives FDA breakthrough therapy designation for Alzheimer's
- 2023: Leqembi receives full FDA approval — landmark in Alzheimer's treatment
- 2024: Expanding neuroscience pipeline with new molecular entities
商业模式
- Neurology: Alzheimer's, epilepsy, migraine — core therapeutic area
- Oncology: Multiple cancer drug candidates in development
- Vitality: GI and other therapeutic areas
- Global partnerships: Co-development with Biogen (Leqembi)
护城河分析
- Alzheimer's leadership: Leqembi positions Eisai at the forefront of Alzheimer's treatment
- R&D focus: 20%+ of revenue invested in R&D — above industry average
- hPHC philosophy: "human health care" philosophy drives patient-centric drug development
- Strategic partnerships: Biogen collaboration shares risk and accelerates development
关键数据
- Revenue: ¥800B+ (~$5.5B) annually
- Leqembi potential: Blockbuster status expected with $5B+ peak sales estimate
- R&D spend: ¥160B+ annually
- Employees: 11,000+ across 30+ countries
有趣事实
- Eisai's name comes from "Eisai" (衛佐), the founder's belief that medicine should "aid and protect" (衛る 佐ける) people's health — the company motto is "ihl" (integrative innovation for health and life)
- The Aricept-Lecanemab journey spans 30+ years of Alzheimer's research at Eisai, making it one of the longest and most committed pharma efforts in the disease
Usage Guidance
This skill appears low-risk from a security perspective because it is only static informational text. As with any reference content, users should independently verify business or medical-market facts before relying on them.
Capability Analysis
Type: OpenClaw Skill
Name: eisas
Version: 1.0.0
The skill bundle contains purely informational content regarding Eisai, a Japanese pharmaceutical company. There is no executable code, shell commands, or instructions that could lead to prompt injection or unauthorized actions in SKILL.md or _meta.json.
Capability Assessment
Purpose & Capability
The artifacts are coherent with an informational research skill about a pharmaceutical company and do not request operational capabilities.
Instruction Scope
The SKILL.md content provides background facts and research context only; it does not instruct the agent to override user intent, call tools, mutate data, or take external actions.
Install Mechanism
There is no install specification, no code files, no required binaries, and no package or script execution.
Credentials
The skill declares no environment variables, credentials, configuration paths, OS restrictions, network access, or local file access.
Persistence & Privilege
No persistence, background behavior, credential use, account access, or privilege requirements are shown in the provided artifacts.
How to Use
- Make sure OpenClaw is installed (local or Docker)
- Run the install command in chat:
/install eisas - After installation, invoke the skill by name or use
/eisas - Provide required inputs per the skill's parameter spec and get structured output
Version History
v1.0.0
eisas 1.0.0
- Initial release highlighting Eisai as a leading Japanese pharmaceutical company focused on CNS drugs and oncology.
- Includes a historical timeline from founding (1941) to latest neuroscience pipeline updates (2024).
- Outlines business model, key therapeutic areas, and global partnerships (notably with Biogen).
- Presents a moat analysis emphasizing Alzheimer's leadership and substantial R&D investment.
- Shares key figures: revenue, R&D spend, employee count, and Leqembi's market impact.
- Adds notable facts about company philosophy and decades-long Alzheimer’s research commitment.
Metadata
Frequently Asked Questions
What is Eisas?
Japanese pharmaceutical company specializing in CNS and oncology drugs, known for Alzheimer's treatments like Aricept and Leqembi in global markets. It is an AI Agent Skill for Claude Code / OpenClaw, with 37 downloads so far.
How do I install Eisas?
Run "/install eisas" in the OpenClaw or Claude Code chat to install it in one step — no extra setup required.
Is Eisas free?
Yes, Eisas is completely free, licensed under MIT-0. You can download, install and use it at no cost.
Which platforms does Eisas support?
Eisas is cross-platform and runs anywhere OpenClaw / Claude Code is available (cross-platform).
Who created Eisas?
It is built and maintained by hanxueyuan (@hanxueyuan); the current version is v1.0.0.
More Skills